Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Biosimilars: SOP for Resin Performance Qualification – V 2.0

Posted on By


Biosimilars: SOP for Resin Performance Qualification – V 2.0


Standard Operating Procedure for Resin Performance Qualification in Biosimilar Manufacturing

Department Biosimilars
SOP No. SOP/BS/199/2025
Supersedes SOP/BS/199/2022
Page No. Page 1 of 10
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To establish a validated and GMP-compliant procedure for qualifying the performance of chromatography resins used in biosimilar purification processes, including assessment of binding capacity, leakage, pressure-flow characteristics, and resin longevity.

2. Scope

This SOP applies to all resins used in protein A, ion-exchange (IEX), hydrophobic interaction chromatography (HIC), and size exclusion chromatography (SEC) operations in downstream processing of biosimilars.

3. Responsibilities

  • Process Development: Define performance specifications and sampling plan.
  • Production: Execute purification runs and collect samples for analysis.
  • QC: Perform analytical testing of collected fractions (titer, HCP, DNA, leakage).
  • QA: Review qualification data and approve resin use beyond initial lifecycle.

4. Accountability

The Head of Manufacturing and Head of Quality Control are accountable for the implementation and lifecycle qualification of chromatography resins in accordance with GMP standards.

5. Procedure

5.1 Resin Selection and Documentation

  1. Ensure all chromatography resins are purchased from approved vendors with CoA and MSDS.
  2. Record resin lot number, batch number, manufacturer, and expiry in Annexure-1.

5.2 Initial Qualification (Baseline Run)

  1. Pack the chromatography column as per validated protocol.
  2. Perform a standard purification cycle using qualified bulk material.
  3. Measure and record:
    • Dynamic binding capacity (DBC) at 10% breakthrough
    • Recovery yield (%)
    • Pressure vs. flow rate profile
    • Leakage of ligand or protein A (Annexure-2)

5.3 Periodic Qualification (Usage-Based)

  1. At defined intervals (e.g., every 10 cycles), repeat DBC and leakage testing.
  2. Monitor changes in pressure-flow behavior and compare with baseline.
  3. Document results in Resin Qualification Log (Annexure-3).

5.4 Acceptance Criteria

  1. DBC should not decrease by more than 20% from initial value.
  2. Ligand leakage (e.g., protein A) must remain within qualified limits (e.g., <10 ppm).
  3. Flow rate at standard pressure must not fall below 80% of baseline.

5.5 Resin Cleaning and Storage

  1. Clean resin using vendor-recommended protocol (e.g., 0.1 M NaOH for Protein A).
  2. Store resin in validated storage buffer at 2–8°C, protected from light.

5.6 Requalification or Discontinuation

  1. If any parameter exceeds acceptance criteria, perform root cause analysis (Annexure-4).
  2. Resin may be:
    • Requalified after additional cleaning and retesting
    • Discarded if unfit for further use
  3. Update resin inventory and lifecycle usage records.

6. Abbreviations

  • DBC: Dynamic Binding Capacity
  • HCP: Host Cell Protein
  • CoA: Certificate of Analysis
  • MSDS: Material Safety Data Sheet

7. Documents

  1. Resin Receipt and Tracking Log – Annexure-1
  2. Baseline Qualification Report – Annexure-2
  3. Resin Performance Log – Annexure-3
  4. Root Cause and Requalification Record – Annexure-4

8. References

  • ICH Q7 – Good Manufacturing Practice for Active Pharmaceutical Ingredients
  • PDA TR No. 60 – Process Validation: A Lifecycle Approach
  • Resin vendor product monographs and technical bulletins

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Resin Receipt and Tracking Log

Resin Name Lot No. Manufacturer Qty (L) Received On Expiry
Protein A MabSelect PA23456 Cytiva 10 01/04/2025 01/04/2028

Annexure-2: Baseline Qualification Report

Date Column ID DBC (mg/mL) Yield (%) Pressure @ Flow Rate Leakage (ppm)
02/04/2025 CH-101 38 92 1.2 bar @ 300 cm/h 5.2

Annexure-3: Resin Performance Log

Cycle No. Date DBC Yield Leakage Status
20 20/04/2025 36 91% 6.1 ppm Pass

Annexure-4: Root Cause and Requalification Record

Date Resin Issue Root Cause Corrective Action Disposition
28/04/2025 Protein A Leakage >10 ppm Inadequate cleaning Repeated CIP with NaOH Requalified

Revision History:

Revision Date Revision No. Details Reason Approved By
04/05/2025 2.0 Included resin leakage and lifecycle limits GMP enhancement
See also  Biosimilars: SOP for Agitation and Aeration Monitoring in Bioreactor Operations - V 2.0
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: Sterile Injection Manufacturing: SOP for Packaging of Temperature-Sensitive Injectable Products – V 2.0
Next Post: Elixir Department: SOP for Real-Time pH Monitoring – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version